FindTrial
Sign In

ANX005

DRUG7 trials

Sponsors

Annexon Inc., Annexon, Inc.

Conditions

Amyotrophic Lateral SclerosisGuillain Barre SyndromeGuillain-Barre SyndromeGuillain-Barré SyndromeHuntington DiseaseSafety and Tolerability in Healthy VolunteersWarm Autoimmune Hemolytic Anemia (wAIHA)

Phase 1

Single Dose Study of ANX005 in Healthy Volunteers
TerminatedNCT03010046
Annexon, Inc.Safety and Tolerability in Healthy Volunteers
Start: 2016-12-31End: 2018-06-30Updated: 2020-08-20
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
CompletedNCT04035135
Annexon, Inc.Guillain-Barré Syndrome
Start: 2020-01-29End: 2021-05-19Updated: 2021-08-11

Phase 2

An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
CompletedNCT04514367
Annexon, Inc.Huntington Disease
Start: 2020-09-29End: 2022-08-29Updated: 2026-08-25
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
CompletedNCT04569435
Annexon, Inc.Amyotrophic Lateral Sclerosis
Start: 2021-01-15End: 2024-04-23Updated: 2025-01-06
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
CompletedNCT04691570
Annexon, Inc.Warm Autoimmune Hemolytic Anemia (wAIHA)
Start: 2021-11-10End: 2023-01-17Updated: 2026-06-30

Phase 3

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
CompletedNCT04701164
Annexon, Inc.Guillain-Barre Syndrome
Start: 2020-12-17End: 2024-04-20Updated: 2025-05-29
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of ANX005 in Participants With Guillain-Barré Syndrome
Not yet recruitingCTIS2025-522664-32-00
Annexon Inc.Guillain Barre Syndrome
Target: 10Updated: 2025-11-20

Related Papers

An Open-Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease.
2026-03-05
J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD)
2022-09-013 citations
P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
HemaSphere2022-06-01
Evidence of Classical Complement Pathway Involvement in a Subset of Patients with Warm Autoimmune Hemolytic Anemia
Blood2021-11-053 citations
I11 Pharmacologic inhibition of the classical complement pathway enhances neuronal function and HD R6/2 mouse survival
2021-09-011 citations
Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases
International Journal of Toxicology2017-11-0198 citations